Pazopanib for the first-line treatment of advanced renal cell carcinoma

  • Technology appraisal guidance
  • TA215
  • Published: 
  • Last updated: 
Download guidance (PDF)

Changes after publication

March 2012: Minor maintenance.

August 2013: Part B of the patient access scheme removed.

April 2017: The company changed from GlaxoSmithKline to Novartis. Contact details for the patient access scheme updated.